Avacopan for the Treatment of ANCA-Associated VasculitisDavid Jayne, Pirow Bekker, Thomas J. Schall et al.|New England Journal of Medicine|2021Cited by 957
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated VasculitisDavid Jayne, Lorraine Harper, Matthias Schaier et al.|Journal of the American Society of Nephrology|2017Cited by 599
A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s DiseaseSatish Keshav, Tomáš Vaňásek, Yaron Niv et al.|PLoS ONE|2013Cited by 134
Risedronate in resistant Paget's disease of boneJelle W. Kylstra, Frederick R. Singer, Pirow Bekker et al.|Bone and Mineral|1992Cited by 5